Severe adverse events attributable to treatment Measured as severe adverse events (all) · infants with SMA and 2 SMN2 copies
Intrathecal injected nusinersen probably leads to lower severe adverse events attributable to treatment Measured as severe… compared with sham procedure (moderate certainty).
1 finding from 1 review
Intervention not reported
Treatment failure · antiretroviral‐naïve individuals
The intervention showed no clear difference in treatment failure (low certainty).
1 finding from 1 review
Intervention not reported
Retention at treatment completion (Any psychosocial intervention vs. control)
The intervention showed no clear difference in retention at treatment completion (Any psychosocial intervention vs.… (low certainty).
1 finding from 1 review
Intervention not reported
Short term treatment retention (Any psychosocial intervention vs. control)
The intervention showed no clear difference in short term treatment retention (Any psychosocial intervention vs.… (low certainty).
1 finding from 1 review
Intervention not reported
Retention at treatment completion (CM vs. control)
The intervention showed no clear difference in retention at treatment completion (CM vs. control) (low certainty).
1 finding from 1 review
Intervention not reported
Retention at treatment completion (MIB interventions vs. control)
The intervention showed no clear difference in retention at treatment completion (MIB interventions vs. control) (low certainty).
1 finding from 1 review
Adverse effects (side effects; treatment withdrawals) · Patients with radiation-induced salivary gland dysfunction
1 finding from 1 review
Johnson 1993 (5 mg tds): sweating 37%, headache 15%, urinary frequency 14%, vasodilatation 12%, dizziness 10%, dyspepsia 10%, nausea 8%, asthenia 8%, diarrhoea 5%; 6% withdrew at 5 mg tds and 29% at 10 mg tds. LeVeque…
2 studies · 278 participants
GRADE not reported
Adverse effects (side effects; treatment withdrawals) · Patients with radiation-induced salivary gland dysfunction
1 finding from 1 review
Davies 1994: main side effects with pilocarpine were nausea 20%, sweating 15%, lacrimation 10%. One participant definitely withdrew because of side effects; another may have.
1 study · 20 participants
GRADE not reported
Intervention not reported
Proportion of patients who discontinued treatment due to adverse events (28 weeks trial period) · Patients between five and 15 years old with a diagnosis of BECTS
The intervention showed no clear difference in proportion of patients who discontinued treatment due to adverse… (low certainty).
1 finding from 1 review
Intervention not reported
Proportion of patients who discontinued treatment due to adverse events (over 6 months trial period) · Patients between three and 10 years old with a diagnosis of BECTS
1 finding from 1 review
Intervention not reported
Proportion of patients who discontinued treatment due to adverse events (96 weeks trial period) · Patients with a clinical and EEG diagnosis of BECTS
It is very uncertain whether the intervention changes proportion of patients who discontinued treatment due to adverse… (very low certainty).
1 finding from 1 review
Intervention not reported
Proportion of patients who discontinued treatment due to adverse events ( · Patients between three and 12 years old with clinical and EEG diagnosis of BECTS
The intervention showed no clear difference in proportion of patients who discontinued treatment due to adverse… (low certainty).
1 finding from 1 review
Drug resistance · patients with initial ART
It is very uncertain whether TDF changes drug resistance compared with AZT (very low certainty).
1 finding from 1 review
Intervention not reported
All‐cause mortality at 2 days ‐ immediate treatment · patients with acute myocardial infarction1
The intervention leads to lower all‐cause mortality at 2 days ‐ immediate treatment (high certainty).
1 finding from 1 review
Intervention not reported
All‐cause mortality at 10 days‐ short‐term treatment · patients with acute myocardial infarction1
The intervention leads to lower all‐cause mortality at 10 days‐ short‐term treatment (high certainty).
1 finding from 1 review
Intervention not reported
All‐cause mortality at 2 days ‐ immediate treatment · acute myocardial infarction1
The intervention showed no clear difference in all‐cause mortality at 2 days ‐ immediate treatment (high certainty).
1 finding from 1 review
Intervention not reported
All‐cause mortality at 10 days ‐ short‐term treatment · acute myocardial infarction1
The intervention leads to lower all‐cause mortality at 10 days ‐ short‐term treatment (high certainty).
1 finding from 1 review
Intervention not reported
All‐cause mortality at 2 days ‐ immediate treatment · patients with acute myocardial infarction1
The intervention showed no clear difference in all‐cause mortality at 2 days ‐ immediate treatment (low certainty).
1 finding from 1 review
Intervention not reported
All‐cause mortality at 10 days ‐ short‐term treatment · patients with acute myocardial infarction1
The intervention showed no clear difference in all‐cause mortality at 10 days ‐ short‐term treatment (high certainty).
1 finding from 1 review
Intervention not reported
All‐cause mortality at 2 days ‐ immediate treatment · patients with acute myocardial infarction or stroke1
It is very uncertain whether the intervention changes all‐cause mortality at 2 days ‐ immediate treatment (very low certainty).
1 finding from 1 review